What is HC Wainwright’s Estimate for NTLA Q1 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Intellia Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($1.40) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.43) EPS and Q4 2026 earnings at ($1.17) EPS.

Several other equities research analysts have also commented on the company. Citigroup upped their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. BMO Capital Markets lowered their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, January 10th. Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. William Blair reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Barclays lowered their price target on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Stock Up 2.9 %

Shares of NASDAQ:NTLA opened at $9.36 on Thursday. The stock has a market cap of $968.92 million, a price-to-earnings ratio of -1.72 and a beta of 1.97. Intellia Therapeutics has a 52-week low of $8.30 and a 52-week high of $32.00. The business has a 50-day moving average price of $10.69 and a 200-day moving average price of $15.32.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 29,000 shares of company stock valued at $352,551 over the last quarter. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of NTLA. Harbor Capital Advisors Inc. boosted its position in shares of Intellia Therapeutics by 71.0% during the third quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company’s stock worth $1,628,000 after buying an additional 32,893 shares during the period. ARK Investment Management LLC boosted its position in shares of Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock worth $251,849,000 after buying an additional 659,651 shares during the period. Lewis Asset Management LLC boosted its position in shares of Intellia Therapeutics by 42.5% during the third quarter. Lewis Asset Management LLC now owns 66,308 shares of the company’s stock worth $1,363,000 after buying an additional 19,775 shares during the period. Atria Investments Inc boosted its position in shares of Intellia Therapeutics by 24.3% during the third quarter. Atria Investments Inc now owns 23,099 shares of the company’s stock worth $475,000 after buying an additional 4,511 shares during the period. Finally, Privium Fund Management B.V. purchased a new position in Intellia Therapeutics in the third quarter valued at $253,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.